Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Poised to branch out

Although dendrimers have not yet taken the drug industry by storm, biomedical research and industrial applications of these tiny, highly branched molecules continue to grow. Vivien Marx reports.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: A conceptualization of DNA-linked dendrimers being internalized by a cell


  1. Mamikunian, V. & Maebius, S. Nanotech IP Battles Worth Fighting. (Lux Research, Foley & Lardner, New York, June 2006).

    Google Scholar 

  2. Lux Research. The Nanotech Report, 5th edn. (Lux Research, New York) 2007.

  3. Dobrovolskaia, M.A. et al. Molecular Pharmaceutics, published online, doi:10.1021/mp800032f, (30 May 2008).

    Article  CAS  Google Scholar 

  4. Swanson, D.R. et al. New J. Chem. 7, 1368–1378 (2007).

    Article  Google Scholar 

  5. Wiener, E.C. et al. Invest Radiol. 32, 748–54 (1997).

    Article  CAS  Google Scholar 

  6. Vetterlein, K. et al. Electrophoresis 28, 3088–3099 (2007).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and permissions

About this article

Cite this article

Marx, V. Poised to branch out. Nat Biotechnol 26, 729–732 (2008).

Download citation

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing